Hangzhou Tigermed Consulting Co., Ltd. disclosed its February 2026 monthly return on securities, confirming that the total authorized share capital remained at RMB 861.03 million. The balance of authorized A shares stood at 737.90 million shares, and H shares remained at 123.12 million shares. Par values were unchanged at RMB 1.00 each.

The number of issued A shares (excluding treasury shares) stayed at 732.02 million, with 5.88 million shares held in treasury. The total issued H shares remained at 123.12 million with no treasury shares. The public float requirement for the H shares was reported as fully compliant. The company also noted that a cumulative 5.88 million A shares remain in treasury following various repurchases from May 2024 to February 2025 and a cancellation of 3.92 million treasury shares on 29 May 2025.